ANIK · Anika Therapeutics, Inc.
$21.50
+0.33 (+1.56%)
At close · Aug 14
View the 10-Q filed Jul 29, 2026
Customer concentration
— top customer 53% of revenue
One customer — 53% of revenue (the three months ended June 30, 2026)
“Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
One customer — 50% of revenue (the six months ended June 30, 2026)
“Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
Market Cap
$287.73M
Shares
13.38M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-07-29 | Q2 2026 Anika Therapeutics Earnings Conference Call | Earnings call |
| 2026-04-29 | Q1 2026 Anika Therapeutics Earnings Conference Call | Earnings call |
| 2026-02-26 | Earnings conference call (announced in 8-K) | Earnings call |
Source: https://ir.anika.com/
Key facts
CIK
898437
CUSIP
035255108
13F (30d)
125 filings
124 filers
Visit website
Investor relations